1. Home
  2. Vol 27, No 7 (2023)
  3. Boublenza

Prevalence of human papillomavirus infection among women at a gynaecological clinic in Tlemcen, Algeria

Lamia Boublenza(1), Amira Nahet(2), Nabila Masdoua(3), Nabila Sadouki(4), Douadi Hamane(5), Ilyes Zatla(6),


(1) Laboratory of Microbiology applied to the Food industry, Biomedical and the Environment. Department of Biology. University of Tlemcen
(2) Laboratory of Microbiology applied to the Food industry, Biomedical and the Environment. Department of Biology. University of Tlemcen
(3) Laboratory of Microbiology applied to the Food industry, Biomedical and the Environment. Department of Biology. University of Tlemcen
(4) Virus and Cancer Laboratory, Pasteur Institut, Algiers
(5) Ibn Sina Medical Analysis Laboratory, Constantine
(6) Laboratory of Microbiology applied to the Food industry, Biomedical and the Environment. Department of Biology. University of Tlemcen
Corresponding Author

Abstract


High-risk human papillomavirus (HR-HPV) is recognized as the etiologic agent responsible for cervical cancer, ranking as the second most prevalent cancer among women in Algeria with an incidence rate of 10.4 per 100,000. The primary aim of this study was to conduct a preliminary prospective investigation into the detection of HR-HPV infections in Tlemcen, Algeria, where screening is exclusively based on cytology. A total of 130 cervical swabs were analysed in this study. HPV detection was performed utilizing the Cobas® 4800 test, incorporating polymerase chain reaction (PCR) for individual genotyping of HPV-16 and HPV-18, as well as pooled detection of 12 other commonly occurring HPVs. The findings revealed that out of the 130 samples, 28 tested positive for HR-HPV, resulting in a prevalence rate of 21.5%. Among these cases, five infections demonstrated the coexistence of HPV16 with other HR-HPV genotypes. The prevalence of HPV16 infections was determined to be 28.6% (8/28), whereas 68% of infections (19/28) were attributed to other HR-HPV genotypes. These observations indicate that HPV16 was not the prevailing genotype. Consequently, these results underscore the necessity for a larger-scale study with an expanded sample size encompassing cytology and HPV testing. Such an investigation would be invaluable in facilitating the development of a national prevention program to effectively control cervical cancer.

References


Ly A. Le cancer utérin : nouveaux vaccins, nouvelles perspectives. J Afr Cancer 2009 ; 1:65–7.

OMS. La lutte contre le cancer du col de l’utérus. Guide des pratiques essentielles. Organisation mondiale de la Santé. Genève, Suisse. 2007.

OMS. Note d’orientation de l’OMS : approche globale de prévention et de lutte contre le cancer du col de l’utérus : vers une meilleure santé pour les femmes et les jeunes filles. Organisation mondiale de la Santé. Genève, Suisse. 2013.

Monsonego J. Infections à papillomavirus. État des connaissances, pratiques et prévention vaccinale. France, Springer-Verlag. 2006.

Globocan. Estimated cancer Incidence, Mortality, Prevalence and Disability-adjusted life years (DALYs) Worldwide in 2008. IARC http://globocan.iarc.fr/. 2008.

Castellsagué X. HPV and Cervical Cancer in the World 2007 Report. Vaccine 2007; 25 (3).

Registre des cancers de Tlemcen. Service d’Epidémiologie et de Médecine Préventive. CHU - Tlemcen. 2006-2010.

Descamps P, Baldauf JJ and Bonnier P. Dépistage des cancers gynécologiques et mammaires. édition Masson ; 2004.

Mougin C, Mo L et Dalstein V. Histoire naturelle des infections à papillomavirus. La revue du praticien 2006 ; 56 : 1883-1889.

Mandran V. Le cancer du col de l’utérin : nouvelles approches avec le test PCR « HPV AMPLICOR ». Journal d’information biomédicale 2005 ; 73 : 28-31.

Riethmuller D. Apport du test HPV. In : Monsonego J. Traité des infections et pathologies génitales à papillomavirus. Paris : Springer ; 2007.p.151 – 158.

Riethmuller D, Ramanah R, Prétet JL and Mougin C. Intégration du test HPV dans le dépistage primaire? Journal de gynécologie obstetrique et biologie de la reproduction 2008 ; 375 : 5139-5151.

Orth G. Les papillomavirus humains et leur rôle dans l’histoire naturelle du cancer du col de l’utérus. Perspectives dans le domaine de la prévention de ce cancer. In : Blanc B. Le dépistage du cancer du col de l’utérus. Paris Springer; 2005. p. 15 – 34.

Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ and Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189 (1): 12-9.

Zur Husen H. Papillomaviruses in the causation of human cancers: a brief historical account. Virology 2009; 384(2): 260-265.

Hammouda D, Clifford GM, Pallardy S, Ayyach G, Chékiri A, Boudrich A, Snijders PJF, van Kemenad FJ, Meijer CJLM, Bouhadef A, Zitouni Z, Habib D, Ikezaren N and Franceschi S. Human papillomavirus infection in a population-based sample of women in Algiers, Algeria. International Journal of Cancer 2011; 128: 2224–2229.

Cobas® 4800 system. Operator’s manuel software version 1.0. Roche diagnostics. 2009.

Cobas® HPV test. Draft package insert, Roche molecular systems Inc. 2011.

Ginocchio CC. Recent Advances in HPV Testing. ASCP Annual meeting. Las vegas. 2011.

Bennani B, El Rhazi K, Bennis S, Nejjari C, Melhouf MA, Zenati K, et al. Hétérogénéité géographique de la prévalence de l’infection à HPV : résultats d’une étude au centre nord du Maroc. J. Afr. Cancer 2011; 3 : 104-110.

Clifford GM, Gallus S, Herrero R, Muñoz N, Snijders PJ, Vaccarella S, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005; 366: 991–998.

Fife KH, Cramer HM, Schroeder JM and Brown DR. Detection of Multiple Human Papillomavirus Types in the Lower Genital Tract Correlates With Cervical Dysplasia. Journal of Medical Virology 2001; 64: 550-559.

Liaw KL, Hildesheim A, Burk RD, Gravitt P, Wacholder Sholom M, Manos M, et al. A Prospective Study of Human Papillomavirus (HPV) Type 16 DNA Detection by Polymerase Chain Reaction and Its Association with Acquisition and Persistence of Other HPV Types. JID 2001; 183: 8–15.

Rousseau MC, Pereira JS, Prado JCM, Villa LL, Rohan TE, Franco EL. Cervical Coinfection with Human Papillomavirus (HPV) Types as a Predictor of Acquisition and Persistence of HPV Infection. JID 2001; 184: 1508–1517.

Van der Graaf Y, Molijn A, Doornewaard H, Quint W, van Doorn LJ and van den Tweel J. Human Papillomavirus and the Long-term Risk of Cervical Neoplasia. Am J Epidemiol 2002; 156 (2) : 158-164.

Trottier H, Mahmud S, Costa MC, Sobrinho JP, Duarte-Franco E, Rohan TE, et al. Human Papillomavirus Infections with Multiple Types and Risk of Cervical Neoplasia. Cancer Epidemiol Biomarkers Prev 2006; 15: 1274-1280.

Levi JE, Kleter B, Quint WGV, Fink MCS, Canto CLM, Matsubara R, et al. High Prevalence of Human Papillomavirus (HPV) Infections and High Frequency of Multiple HPV Genotypes in Human Immunodeficiency Virus-Infected Women in Brazil. J. Clin. Microbiol 2002; 40(9): 3341-3345.

Levi JE, Fernandez S, Tateno AF, Lima LP, Eluf-Neto J and Pannuti CS. Presence of multiple human papillomavirus types in cervical samples from HIV-infected women. Gynecologic Oncology 2004 ; 92: 225–231.

Jong E, Mulder JW, van Gorp EC, Wagenaar JK, Derksen J, Westerga J, Tol A and Smits PHM. The prevalence of human papillomavirus (HPV) infection in paired urine and cervical smear samples of HIV-infected women. Journal of Clinical Virology 2008 ; 41 : 111–115.

Monsonego J. Traité des infections et pathologies génitales à papillomavirus. Paris : Springer ; 2007.

Hammouda D, Muñoz N, Herrero R, Arslan A, Bouhadef A, Oublil M, Djedeat B, Fontaniere B, Snidjers P, Meijer C and Franceschi S. Cervical Carcinoma in Algiers, Algeria: Human Papillomavirus and Lifestyle Risk Factors. Int. J. Cancer 2005; 113: 483–489.

Smith JS, Melendy A, Rana RK and Pimenta JM. Age-Specific Prevalence of Infection with Human Papillomavirus in Females: A Global Review. Journal of Adolescent Health 2008; 43: 5–25.

De Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N and Bosch FX. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007 ; 7: 453–459.

Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch F X, and De Sanjose S. Cervical Human Papillomavirus Prevalence in 5 Continents: Meta-Analysis of 1 Million Women with Normal Cytological Findings. JID 2010 ; 202(12): 1789–1799.

Castellsagué X and Mũnoz N. Chapter 3: Cofactors in Human Papillomavirus Carcinogenesis—Role of Parity, Oral Contraceptives, and Tobacco Smoking. Journal of the National Cancer Institute Monographs 2003; 31 : 20-28.

Meurice F. Vaccination prophylactique contre le HPV : que savons-nous déjà et quelles sont les principales questions en suspens. In : Monsonego J. Traité des infections et pathologies génitales à papillomavirus. Paris: Springer ; 2007. p. 497-504.

Bosch X and De Sanjosé . The epidemiology of human papillomavirus infection and cervical cancer. Disease Markers 2007; 23 : 213–227.

Monsonego J. Prévention du cancer du col utérin : apport du dépistage. récents progrès et perspectives. Presse médicale tom 2007 ; 36 (1) 105.

Lolerie V. Technologie Hybrid Capture. In : Monsonego J Traité des infections et pathologies génitales à papillomavirus. Paris : Springer ; 2007. p. 43 – 46.


Full Text: PDF

Article Metrics

Abstract View : 636 times
PDF Download : 360 times

Refbacks

  • There are currently no refbacks.